Nerelimomab

奈瑞莫单抗

Report date: 2022/01/14 13:23:58

Base Information

Drug NameNerelimomab
Drug Alias NameBAY 1351NoraseptBAY X 1351BAY-1351
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine
Mechanisms of ActionImmunosuppressantsTumor necrosis factor inhibitors
TargetsTumor necrosis factor
Therapy Area/IndicationsShock, Septic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCelltechChiron Spa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChironCelltechBayer AG
Active IndicationsN/A
Inactive IndicationsShock, Septic

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG